Emtricitabine Drug Asset Due Diligence Report 2026

This Emtricitabine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

162

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Emtricitabine can convert its Small molecule drug profile and RT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Emtricitabine (query alias: emtricitabine)
Modality / target	Small molecule drug; RT; RT inhibitors
Highest global status	Approved
Originator	Gilead Sciences, Inc.
Active developers	Gilead Sciences Ireland UC, Hebei Medical University Pharmaceutical Factory, Gilead Sciences, Inc.

The MCP disease footprint includes HIV Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06719310	Phase 1/2	Recruiting	36	Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE
NCT07210528	Phase 1	Recruiting	48	Number of participants with treatment-related Adverse/Serious Adverse Events (AE/SAE)
NCT07062614	Not Applicable	Recruiting	30	Individuality index for each patient

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.

Phase 2; n=210; evaluation: Positive. Reported fields: Treatment Success = 57 % (95%CI, 47 - 66); -; Treatment Success = 59 % (95%CI, 49 - 68)

Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study)

Phase 4; n=30; evaluation: Positive. Reported fields: Adverse Event: IRIS = Two participants developed IRIS

Quantification of Estradiol's Impact on Nucleotides in Different Cellular Populations of the Lower Gastrointestinal Tract

Phase 1; n=10; evaluation: not stated. Reported fields: Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle.(Mean) = 406.14 fmol/million cells (Standard Deviation, 819.0428); Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle.(Mean): Spearman's Rho = -0.455; Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle.(Mean): Spearman's Rho = -0.455

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Emtricitabine addresses HIV Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-11-29	JT Terminates Agreements with Gilead Sciences on Exclusive Rights to Develop, Commercialize and Market of Six Anti-HIV Drugs in Japan	Approved	Financial terms not disclosed
1996-01-01	GILEAD SCIENCES AND ROYALTY PHARMA ANNOUNCE $525 MILLION AGREEMENT WITH EMORY UNIVERSITY TO PURCHASE ROYALTY INTEREST FOR EMTRICITABINE	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “A method for formulation of tenofovir and emtricitabine sustained release tablet”. The milestone feed surfaced a patent-application signal described as “Synthesis method of emtricitabine”. The milestone feed surfaced a patent-application signal described as “Computerized decision support tool and medical device for respiratory tract condition monitoring and care”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO